SCOTTSDALE, Ariz.--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX Venture:IXS) (OTCBB: IXSBF) (www.ixsbio.com), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, announced today the addition of noted clinical oncologist and cancer research pioneer Daniel Von Hoff, M.D. to the InNexus Scientific Advisory Board.
